Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
Alex Delaney-Gesing
Elizabeth Yeu, MD, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of TP03 for the treatment of patients diagnosed with Demodex blepharitis.
Elizabeth Yeu, MD, a cornea cataract and refractive surgeon at Virginia Eye Consultants, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of a new investigational therapeutic from Tarsus Pharmaceuticals called TP03 (lotilaner ophthalmic solution 0.25%), for the treatment of patients diagnosed with Demodex blepharitis.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Articles
- Q&A: Anat Loewenstein recaps the 2025 EURETINA meeting
September 22nd 2025
- Q&A: Robyn Guymer highlights risk factors of intermediate AMD
September 20th 2025
- Investigators share positive results of DAVIO 2 trial at EURETINA 2025
September 18th 2025